LDLennard J. M. Dekker

Lennard J. M. Dekker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lennard J. M. Dekker has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study

    by Sophie C. Hagenaars, Lennard J. M. Dekker, Bob Ravesteijn, Ronald L. P. van Vlierberghe, Fred P. H. T. M. Romijn, Linda Verhoeff, Arjen J. Witkamp, Karin E. Schenk, Kristien B. I. M. Keymeulen, Marian B. E. Menke-Pluijmers, et al.

    The prospective, multicenter TESTBREAST study was initiated with the aim of identifying a novel panel of blood-based protein biomarkers to enable early breast cancer detection for moderate-to-high-risk women. Serum samples were collected every (half) year up until diagnosis. Protein levels were longitudinally measured to determine intrapatient and interpatient variabilities. To this end, protein cluster patterns were evaluated to form a conceptual basis for further clinical analyses. Using a mass spectrometry-based bottom-up proteomics strategy, the protein abundance of 30 samples was analyzed: five sequential serum samples from six high-risk women; three who developed a breast malignancy (cases) and three who did not (controls). Serum samples were chromatographically fractionated and an in-depth serum proteome was acquired. Cluster analyses were applied to indicate differences between and within protein levels in serum samples of individuals. Statistical analyses were performed using ANOVA to select proteins with a high level of clustering. Cluster analyses on 30 serum samples revealed unique patterns of protein clustering for each patient, indicating a greater interpatient than intrapatient variability in protein levels of the longitudinally acquired samples. Moreover, the most distinctive proteins in the cluster analysis were identified. Strong clustering patterns within longitudinal intrapatient samples have demonstrated the importance of identifying small changes in protein levels for individuals over time. This underlines the significance of longitudinal serum measurements, that patients can serve as their own controls, and the relevance of the current study set-up for early detection. The TESTBREAST study will continue its pursuit toward establishing a protein panel for early breast cancer detection.


  • A hydroxylated collagen peptide in urine as biomarker for the detection of colorectal liver metastases.

    by Robert R.J. Coebergh van Den Braak, Zarina S. Lalmahomed, Mirelle E. Brã¶Ker, Nick A. van Huizen, Lennard J.M. Dekker, Cornelis Verhoef, Ewout W. Steyerberg, Dimitris Rizopoulos, Theo M. Luider, Jan N.M. Ijzermans

    E15081 Background: Of all patients undergoing curative surgery for primary colorectal cancer, 40% will have or develop colorectal liver metastases (CRLM). Therefore, these patients are monitored for five years using a combination of serum CarcinoEmbryogenic Antigen (CEA) levels and imaging. With a sensitivity of 64%, the value of CEA as a biomarker to detect CRLM is limited. In 2010, our group identified and validated the occurence of a specifically hydroxylated collagen peptide AGPP(-OH)GEAGKP(-OH)GEQGVP(-OH)GDLGAP(-OH)GP (AGP) in a significantly higher concentration in urine samples of patients with CRLM compared to urine samples of healthy kidney donors using mass spectrometry. The current study aimed to assess the sensitivity and specificity of the AGP concentration in urine combined with serum CEA level. Methods: Urine samples were collected from 100 patients with CRLM and three control groups: healthy kidney donors (n = 100), patients with a minimum disease free interval of 24 months after metastasectomy of CRLM (n = 20) and patients with localized primary colorectal cancer (n = 18). A stable isotope labeled peptide was used to determine the concentration of AGP in the urine samples using mass spectrometry. Results: The sensitivity for serum CEA level and AGP concentration in urine was 66% and 68% respectively. Serum CEA levels and urine AGP levels did not correlate (r2= 0.08) and, therefore, were complementary. Combining serum CEA level and AGP concentration in urine produced a significant increase in sensitivity to 85% compared to serum CEA level alone (p < 0.001) with an acceptable decrease of specificity from 91% to 84%. Conclusions: The concentration of AGP in urine may be a useful biomarker to detect CRLM in patients after curative resection of colorectal cancer. Longitudinal sampling is expected to be of value and improve the sensitivity, as increases within patients can be monitored.


  • An integrated top‐down and bottom‐up proteomic approach to characterize the antigen‐binding fragment of antibodies

    by Lennard Dekker, Si Wu, Martijn Vanduijn, Nikolai Tolić, Christoph Stingl, Rui Zhao, Theo Luider, Ljiljana Paša‐Tolić

    We have previously shown that different individuals exposed to the same antigen produce antibodies with identical mutations in their complementarity determining regions (CDR), suggesting that CDR tryptic peptides can serve as biomarkers for disease diagnosis and prognosis. Complete Fabs derived from disease specific antibodies have even higher potential; they could potentially be used for disease treatment and are required to identify the antigens toward which the antibodies are directed. However, complete Fab sequence characterization via LC‐MS analysis of tryptic peptides (i.e. bottom‐up) has proven to be impractical for mixtures of antibodies. To tackle this challenge, we have developed an integrated bottom‐up and top‐down MS approach, employing 2D chromatography coupled with Fourier transform mass spectrometry (FTMS), and applied this approach for full characterization of the variable parts of two pharmaceutical monoclonal antibodies with sensitivity comparable to the bottom‐up standard. These efforts represent an essential step toward the identification of disease specific antibodies in patient samples with potentially significant clinical impact.


  • Comparative Study of Targeted and Label-free Mass Spectrometry Methods for Protein Quantification

    by Linda Ijsselstijn, Marcel P. Stoop, Christoph Stingl, Peter A. E. Sillevis Smitt, Theo M. Luider, Lennard J. M. Dekker


  • Open Access

    Label-free peptide profiling of Orbitrap™ full mass spectra

    by Mark K Titulaer, Dominique de Costa, Christoph Stingl, Lennard J Dekker, Peter Ae Sillevis Smitt, Theo M Luider

    We developed a new version of the open source software package Peptrix that can yet compare large numbers of Orbitrap™ LC-MS data. The peptide profiling results for Peptrix on MS1 spectra were compared with those obtained from a small selection of open source and commercial software packages: msInspect, Sieve™ and Progenesis™. The properties compared in these packages were speed, total number of detected masses, redundancy of masses, reproducibility in numbers and CV of intensity, overlap of masses, and differences in peptide peak intensities. Reproducibility measurements were taken for the different MS1 software applications by measuring in triplicate a complex peptide mixture of immunoglobulin on the Orbitrap™ mass spectrometer. Values of peptide masses detected from the high intensity peaks of the MS1 spectra by peptide profiling were verified with values of the MS2 fragmented and sequenced masses that resulted in protein identifications with a significant score.


  • A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors

    by Lennard J. M. Dekker, Jeroen J. A. van Kampen, Mariska L. Reedijk, Peter C. Burgers, Rob A. Gruters, Albert D. M. E. Osterhaus, Theo M. Luider

    Mass spectrometry imaging is a promising technique for measuring drugs and drug metabolites in cells and tissues. In this manuscript we describe a method for the imaging of HIV protease inhibitors. As a model system we used Mono Mac 6 cells cultured with the HIV protease inhibitors saquinavir and nelfinavir deposited on glass slides using a cytocentrifuge. A sublimation/deposition device for homogeneous matrix deposition was constructed which allows imaging of these HIV protease inhibitors at clinically relevant concentrations. Using this matrix sublimation/deposition method, glass slides containing the cytocentrifuged cells can be measured and analyzed by two types of mass spectrometry techniques, viz. matrix‐assisted laser desorption/ionization time‐of‐flight (MALDI‐TOF) and MALDI Fourier transform ion cyclotron resonance (FTICR), and this makes it possible to perform imaging rapidly (MALDI‐TOF) and with a very high selectivity (MALDI‐FTICR). Copyright © 2009 John Wiley & Sons, Ltd.


  • Depletion of high-abundance proteins from serum by immunoaffinity chromatography: A MALDI-FT-MS study

    by Lennard J. Dekker, Jan Bosman, Peter C. Burgers, Angelique van Rijswijk, Robert Freije, Theo Luider, Rainer Bischoff


  • Open Access

    A database application for pre-processing, storage and comparison of mass spectra derived from patients and controls

    by Mark K Titulaer, Ivar Siccama, Lennard J Dekker, Angelique Lct van Rijswijk, Ron Ma Heeren, Peter A Sillevis Smitt, Theo M Luider


  • Peptide profiling of cerebrospinal fluid by mass spectrometry

    by Lennard J Dekker, Peter C Burgers, Johan M Kros, Peter Ae Sillevis Smitt, Theo M Luider

    The search for biomarkers is driven by the increasing clinical importance of early diagnosis. Reliable biomarkers can also assist in directing therapy, monitoring disease activity and the efficacy of treatment. In addition, the discovery of novel biomarkers might provide clues to the pathogenesis of a disease. The dynamic range of protein concentrations in body fluids exceeds 10 orders of magnitude. These huge differences in concentrations complicate the detection of proteins with low expression levels. Since all classical biomarkers have low expression levels (e.g., prostate-specific antigen: 2-4 μg/l; and CA125: 20-35 U/ml), new developments with respect to identification and validation techniques of the low-abundance proteins are required. This review will discuss the current status of profiling cerebrospinal fluid using mass spectrometry-based techniques, and new developments in this area